New drug targets 'Undruggable' cancer mutation in first human trial

NCT ID NCT07023731

Summary

This is the first study to test a new drug called ARV-806 in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to find a safe dose and see how the body processes the drug, while also looking for early signs that it can shrink tumors. The study is open to adults with advanced cancers who have tried standard treatments, with a special focus in later stages on pancreatic cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Trial Site

    RECRUITING

    Phoenix, Arizona, 85004, United States

  • Clinical Trial Site

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Clinical Trial Site

    RECRUITING

    New Haven, Connecticut, 06510, United States

  • Clinical Trial Site

    RECRUITING

    Tampa, Florida, 33612, United States

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Clinical Trial Site

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Clinical Trial Site

    RECRUITING

    New York, New York, 10032, United States

  • Clinical Trial Site

    RECRUITING

    New York, New York, 10065, United States

  • Clinical Trial Site

    RECRUITING

    Huntersville, North Carolina, 28078, United States

  • Clinical Trial Site

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • Clinical Trial Site

    RECRUITING

    Houston, Texas, 77030-7009, United States

  • Clinical Trial Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Clinical Trial Site

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Clinical Trial Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.